Targeted Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Targeted Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

  • Transparency Market Research
  • May 2021
  • Pharmaceutical
  • 224 pages

Report Description

Targeted Therapeutics Market – Scope of the Report

TMR’s report on the global targeted therapeutics market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period 2021 to 2031. The report provides the overall value (US$ Mn) of the global targeted therapeutics market for the period of 2017–2031, considering 2017–2019 as historical years, 2020 as the base year, and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global targeted therapeutics market for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global targeted therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global targeted therapeutics market.

The report comprises an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global targeted therapeutics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global targeted therapeutics market. The next section of the global targeted therapeutics market report highlights the USPs, which include disease prevalence and incidence rate of cancer, clinical trial pipeline analysis, key industry events, and impact of COVID-19 on the global targeted therapeutics market.

The report delves into the competitive landscape of the global targeted therapeutics market. Key players operating in the global targeted therapeutics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global targeted therapeutics market report.

Key Questions Answered in Targeted Therapeutics Market Report

  • What is the sales/revenue generated by the global targeted therapeutics market across all the regions during the forecast period?
  • What are the key trends in the global targeted therapeutics market?
  • What are the major drivers, restraints, and opportunities in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2031 and which application will expand at the fastest CAGR during the forecast period?

Targeted Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global targeted therapeutics market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global targeted therapeutics market. It is followed by market introduction, market dynamics, and an overview of the global targeted therapeutics market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the targeted therapeutics market. The next section of the global targeted therapeutics market report highlights the USPs, which include disease prevalence and incidence rate of cancer, clinical trial pipeline analysis, key industry events, and impact of COVID-19 on the global targeted therapeutics market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by leading targeted therapeutics has been mapped to ascertain the size of the global targeted therapeutics market in terms of value. The forecast presented here assesses the total revenue generated in the targeted therapeutics market. In order to provide an accurate forecast, we initiated by sizing up the current targeted therapeutics market with the help of the parent market.

The report analyzes the global targeted therapeutics market in terms of type, application, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the global targeted therapeutics market.

Global Targeted Therapeutics Market: Segmentation

Targeted Therapeutics Market, by Type

  • Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • HER-2 Targeted Agents
  • Anti-CD20 Monoclonal Antibodies
  • Small Molecule
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • PARP Inhibitors

Targeted Therapeutics Market, by Application

  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Sclerosis
  • Renal Cancer
  • Wet Age-related Macular Degeneration
  • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)

Targeted Therapeutics Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Targeted Therapeutics Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Have query on this report?

Make an Enquiry

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Targeted Therapeutics Market

4. Market Overview

4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Cancer Prevalence and Incidence Rate by Key Region
5.2. Clinical Trial Pipeline Analysis
5.3. Key Industry Events
5.4. COVID-19 Pandemics Impact on Global Targeted Therapeutics Market

6. Global Targeted Therapeutics Market Analysis and Forecast, by Type 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.1.1. Angiogenesis Inhibitors
6.3.1.2. HER-2 Targeted Agents
6.3.1.3. Anti-CD20 Monoclonal Antibodies
6.3.2. Small Molecule
6.3.2.1. Tyrosine Kinase Inhibitors
6.3.2.2. mTOR Inhibitors
6.3.2.3. PARP Inhibitors
6.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Type 

7. Global Targeted Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Colorectal Cancer
7.3.3. Leukemia
7.3.4. Lung Cancer
7.3.5. Lymphoma
7.3.6. Multiple Sclerosis
7.3.7. Renal Cancer
7.3.8. Wet Age-related Macular Degeneration
7.3.9. Others
7.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Application 

8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel 
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel 

9. Global Targeted Therapeutics Market Analysis and Forecast, by Region 
9.1. Key Findings
9.2. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region
9.2.1. North America 
9.2.2. Europe 
9.2.3. Asia Pacific
9.2.4. Latin America 
9.2.5. Middle East & Africa
9.3. Global Targeted Therapeutics Market Attractiveness Analysis, by Region

10. North America Targeted Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.1.1. Angiogenesis Inhibitors
10.2.1.2. HER-2 Targeted Agents
10.2.1.3. Anti-CD20 Monoclonal Antibodies
10.2.2. Small Molecule
10.2.2.1. Tyrosine Kinase Inhibitors
10.2.2.2. mTOR Inhibitors
10.2.2.3. PARP Inhibitors
10.3. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Leukemia
10.3.4. Lung Cancer
10.3.5. Lymphoma
10.3.6. Multiple Sclerosis
10.3.7. Renal Cancer
10.3.8. Wet Age-related Macular Degeneration
10.3.9. Others
10.4. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Targeted Therapeutics Market Attractiveness Analysis
10.6.1. By Type 
10.6.2. By Distribution Channel 
10.6.3. By Country

11. Europe Targeted Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.1.1. Angiogenesis Inhibitors
11.2.1.2. HER-2 Targeted Agents
11.2.1.3. Anti-CD20 Monoclonal Antibodies
11.2.2. Small Molecule
11.2.2.1. Tyrosine Kinase Inhibitors
11.2.2.2. mTOR Inhibitors
11.2.2.3. PARP Inhibitors
11.3. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
11.3.1. Breast Cancer
11.3.2. Colorectal Cancer
11.3.3. Leukemia
11.3.4. Lung Cancer
11.3.5. Lymphoma
11.3.6. Multiple Sclerosis
11.3.7. Renal Cancer
11.3.8. Wet Age-related Macular Degeneration
11.3.9. Others
11.4. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe 
11.6. Europe Targeted Therapeutics Market Attractiveness Analysis
11.6.1. By Type  
11.6.2. By Distribution Channel 
11.6.3. By Country/Sub-region

12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.1.1. Angiogenesis Inhibitors
12.2.1.2. HER-2 Targeted Agents
12.2.1.3. Anti-CD20 Monoclonal Antibodies
12.2.2. Small Molecule
12.2.2.1. Tyrosine Kinase Inhibitors
12.2.2.2. mTOR Inhibitors
12.2.2.3. PARP Inhibitors
12.3. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Leukemia
12.3.4. Lung Cancer
12.3.5. Lymphoma
12.3.6. Multiple Sclerosis
12.3.7. Renal Cancer
12.3.8. Wet Age-related Macular Degeneration
12.3.9. Others
12.4. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Targeted Therapeutics Market Attractiveness Analysis
12.6.1. By Type 
12.6.2. By Distribution Channel 
12.6.3. By Country/Sub-region

13. Latin America Targeted Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.1.1. Angiogenesis Inhibitors
13.2.1.2. HER-2 Targeted Agents
13.2.1.3. Anti-CD20 Monoclonal Antibodies
13.2.2. Small Molecule
13.2.2.1. Tyrosine Kinase Inhibitors
13.2.2.2. mTOR Inhibitors
13.2.2.3. PARP Inhibitors
13.3. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
13.3.1. Breast Cancer
13.3.2. Colorectal Cancer
13.3.3. Leukemia
13.3.4. Lung Cancer
13.3.5. Lymphoma
13.3.6. Multiple Sclerosis
13.3.7. Renal Cancer
13.3.8. Wet Age-related Macular Degeneration
13.3.9. Others
13.4. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Targeted Therapeutics Market Attractiveness Analysis
13.6.1. By Type 
13.6.2. By Distribution Channel 
13.6.3. By Country/Sub-region

14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.1.1. Angiogenesis Inhibitors
14.2.1.2. HER-2 Targeted Agents
14.2.1.3. Anti-CD20 Monoclonal Antibodies
14.2.2. Small Molecule
14.2.2.1. Tyrosine Kinase Inhibitors
14.2.2.2. mTOR Inhibitors
14.2.2.3. PARP Inhibitors
14.3. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
14.3.1. Breast Cancer
14.3.2. Colorectal Cancer
14.3.3. Leukemia
14.3.4. Lung Cancer
14.3.5. Lymphoma
14.3.6. Multiple Sclerosis
14.3.7. Renal Cancer
14.3.8. Wet Age-related Macular Degeneration
14.3.9. Others
14.4. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis
14.6.1. By Type 
14.6.2. By Distribution Channel 
14.6.3. By Country/Sub-region

15. Competitive Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Sanofi
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. GlaxoSmithKline plc
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. Merck & Co., Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Novartis AG 
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Merck KGaA
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Pfizer Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. F. Hoffmann-La Roche Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. AstraZeneca
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. Seagen, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis
15.2.11. Bayer AG
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis
15.2.12. Amgen, Inc.
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Strategic Overview
15.2.12.5. SWOT Analysis
15.2.13. Bristol-Myers Squibb Company
15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.13.2. Financial Overview
15.2.13.3. Product Portfolio
15.2.13.4. Strategic Overview
15.2.13.5. SWOT Analysis

List of Tables

Table 01: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017-2031
Table 03: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017-2031
Table 04: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 05: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 10: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule , 2017–2031
Table 11: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 16: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 17: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 19: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 21: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 22: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 23: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 27: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 28: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 29: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 32: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 33: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 34: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 35: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Success Stories

Our Clients